SCII Stem Cell Therapy International Corporation featured news, full reports, and detailed charts
Stem Cell Therapy International Corporation (SCII/SCII.OB) Wrap Up:
Stem Cell Therapy International, Inc., through its subsidiary, Stem Cell Therapy International Corp., engages in licensing of stem cell technology and the sale of stem cell products, as well as the provision of information, education, and referral services. It offers allo stem cell biological solutions that are used in the treatment of patients suffering from degenerative disorders of the human body, such as Alzheimer's Disease, Parkinson's Disease, ALS, leukemia, muscular dystrophy, multiple sclerosis, arthritis, spinal cord injuries, brain injury, stroke, heart disease, liver and retinal disease, and diabetes, as well as certain types of cancer. The company’s stem cell biological solutions...www.scticorp.com
2 Employees
Founded in 2004
Stem Cell Therapy International Corporation (SCII:OTC Bulletin Board Market)
LAST $0.12 USD
CHANGE TODAY -0.016 -11.76%
VOLUME 157.6K
As of 3:58 PM 11/20/09 All times are local (Market data by Reuters is delayed by at least 15 minutes).
Snapshot of Stem Cell Therapy International Corporation (SCII)
|
OPEN
$0.13
|
PREVIOUS CLOSE
$0.14
|
|
|
DAY HIGH
$0.13
|
DAY LOW
$0.12
|
|
|
52 WEEK HIGH
09/16/09 - $0.50
|
52 WEEK LOW
11/24/08 - $0.02
|
|
|
MARKET CAP
7.9M
|
AVERAGE VOLUME 3 mo
131.5K
|
|
|
DILUTED EPS TTM
--
|
SHARES OUTSTANDING
65.4M
|
|
|
SCII Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
SCII Top Compensated Officers
Dr. David L. Stark Q.M.E., CCRA
Chairman, Chief Executive Officer, President ...
Age: 51
Total Annual Compensation: $225.0K
Mr. Calvin C. Cao
Co-Founder and Director
Age: 42
Total Annual Compensation: $150.0K
Mr. Andrew J. Norstrud
Chief Financial Officer, Chief Accounting Off...
Age: 35
Total Annual Compensation: $60.0K
Mr. Lixian Jiang
Chief Operating Officer, Patent Trademark Cou...
Age: 37
Total Annual Compensation: $60.0K
Executives, Board Directors
Compensation as of Fiscal Year 2009.
Key developments for Stem Cell Therapy International Corporation (SCII)
Stem Cell Therapy International Corporation Approves Amendments to Articles of Incorporation
11/2/2009
Stem Cell Therapy International Corporation approved to amend its Articles of Incorporation to effect an increase in the company's authorized shares of common stock to 500,000,000 shares.
Stem Cell Therapy International Corporation has Changed its Name to AmStem Corporation
11/2/2009
Stem Cell Therapy International Corporation changed its name to AmStem Corporation
Stem Cell Therapy Mulls Acquisitions
10/28/2009
Stem Cell Therapy International Corporation plans to accelerate its growth through the strategic acquisitions of companies that will enhance or compliment its current service or product offerings. Each component of the Company plays an important roll in the strategy of driving long term, sustainable value for our shareholders.
SCII Competitors
| Company | Last | Change |
| Cord Blood America Inc | $0.0049 USD | -0.0003 |
| Cryo-Cell Intl Inc | $1.82 USD | -0.02 |
| International Stem Cell Corp | $0.58 USD | -0.04 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | SCII | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
|
SCII |
||
SCII transactions
| Type Date |
Target |
|
Private Placement
November 3, 2009 |
-- |
More Recent News About Stem Cell Therapy International Corporation
Would you like to leave a comment about Stem Cell Therapy International Corporation SCII/SCII.OB
Find out what social network information about Stem Cell Therapy International Corporation are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Stem Cell Therapy International Corporation there is more great information available at Realpennies.com